However, clinical trials confirmed that [254, 255, 256] a low dose of IL‐2 selectively expands regulatory T cells and maintains their suppressive functions, increases the Tr/Th ratio in mice [257] and SLE patients [258, 259], modulates Tfh cells and Th17 cells [256], expands NK cells [255], inhibits dsDNA antibodies, and improves renal conditions. This evidence concerns the gene IL2 and systemic lupus erythematosus.